Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

G1 Therapeutics Inc (NQ: GTHX )

3.670 +0.040 (+1.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about G1 Therapeutics Inc

< Previous 1 2 3 4 Next >
G1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025
While there’s no denying that G1 Therapeutics stock is highly speculative, investors should still check under the hood. 
Via InvestorPlace
Biotech Bombshell: G1 Therapeutics Stock Is Too Much of a Gamble
G1 Therapeutics stock is highly volatile, and investors should be wary now as G1 Therapeutics recently failed to achieve a clinical goal. 
Via InvestorPlace
Ball To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Coffee Recall 2024: Over 250 Coffee Products Recalled Due to Botulism Fears
A 2024 coffee recall is in effect for products made by Snapchill LLC due to concerns of botulism from the FDA for hundreds of canned coffees. 
Via InvestorPlace
Exposures Product Safety
Ginkgo Bioworks Layoffs 2024: What to Know About the Latest DNA Job Cuts
Ginkgo Bioworks layoffs are a hot topic as the company prepares to cut 158 jobs this week with more headcount reductions coming next week. 
Via InvestorPlace
Topics Workforce
Exposures Layoff
Analyst Ratings For G1 Therapeutics
Via Benzinga
Evaluating G1 Therapeutics: Insights From 5 Financial Analysts
Via Benzinga
Breaking Down G1 Therapeutics: 5 Analysts Share Their Views
Via Benzinga
Forecasting The Future: 5 Analyst Projections For G1 Therapeutics
Via Benzinga
Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge
Alnylam Pharmaceuticals reports positive results from the HELIOS-B Phase 3 study of vutrisiran for ATTR amyloidosis with cardiomyopathy. The trial showed significant reductions in mortality and... 
Via Benzinga
Why Is Cancer-Focused G1 Therapeutics Stock Trading Lower On Monday?
Shares of G1 Therapeutics are down after release of Phase 3 trial results for trilaciclib in TNBC. 
Via Benzinga
Why Is G1 Therapeutics (GTHX) Stock Down 56% Today?
G1 Therapeutics stock is down on Monday as GTHX investors react to the company's Phase 3 clinical trial of trilaciclib failing. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news on Monday morning! 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
What's Going On With G1 Therapeutics Stock?
According to a report, G1 Therapeutics has received and rejected multiple offers from TerSera Therapeutics. According to the report, one offer from TerSera is rumored to have a contingent value right... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
GTHX Stock Earnings: G1 Therapeutics Beats EPS, Misses Revenue for Q1 2024
GTHX stock results show that G1 Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Is Breast Cancer-Focused G1 Therapeutics Stock Trading Lower Today?
Follow G1 Therapeutics as it advances trilaciclib in Phase 3 PRESERVE 2 trial for metastatic triple-negative breast cancer. Updates on trial progress, interim analysis, and potential FDA filing in... 
Via Benzinga
Exposures Product Safety
Why IPG Photonics Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of IPG Photonics Corporation (NASDAQ: IPGP) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued soft first-quarter guidance. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Evercore ISI Is Warming Up to NextEra Energy (NEE) Stock
NextEra Energy stock is on the move Tuesday after Evercore ISI initiated coverage of NEE shares with a bull rating and price target. 
Via InvestorPlace
UBS Just Upped Its Nvidia (NVDA) Stock Price Target
Nvidia stock is a hot topic among NVDA traders on Tuesday after the company's shares got a new $850 price target from UBS analysts. 
Via InvestorPlace
Why ZoomInfo Technologies Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket
Shares of ZoomInfo Technologies Inc. (NASDAQ: ZI) rose sharply in today’s pre-market trading as the company reported stronger-than-expected fourth-quarter financial results. 
Via Benzinga
Why Is Polished.com (POL) Stock Down 33% Today?
Polished.com stock is sliding lower on Tuesday as investors in POL react to the company missing a debt payment and other dangers. 
Via InvestorPlace
Why Is G1 Therapeutics (GTHX) Stock Down 45% Today?
G1 Therapeutics stock is down on Tuesday after the company provided GTHX investors with an update on a Phase 3 clinical trial. 
Via InvestorPlace
ZoomInfo Technologies To Rally Around 50%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.